<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="19978">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01860911</url>
  </required_header>
  <id_info>
    <org_study_id>12-005173</org_study_id>
    <nct_id>NCT01860911</nct_id>
  </id_info>
  <brief_title>Plasma Triglyceride Extraction by The Muscle</brief_title>
  <official_title>Regulation of the Plasma Triglyceride Extraction in Muscle in Insulin Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Diabetes Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Increased accumulation of fat into the muscles is associated with what is called
      insulin-resistant state, which is a pre-diabetic state. The purpose of this research is to
      find out how fat circulating in the blood following fat consumption is taken up by the
      muscles in healthy people as well as people that are insulin-resistant. The investigators
      are specifically interested in how a hormone called insulin is involved in this process.
      Findings from this research will contribute to our understanding of why insulin-resistant
      people have increased accumulation of fat in their muscles, and ultimately help to design
      appropriate interventions to prevent type 2 Diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Triglyceride extraction across the forearm</measure>
    <time_frame>Measured during a 7-hour infusion study</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Muscle microvascular blood volume</measure>
    <time_frame>Selected 15-minute periods during the 7 hour infusion study</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Obesity</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Insulin-Sensitive</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One group consists of insulin sensitive volunteers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin-Resistant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One group consists of insulin resistant volunteers.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <arm_group_label>Insulin-Sensitive</arm_group_label>
    <arm_group_label>Insulin-Resistant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NG-monomethyl-L-arginine</intervention_name>
    <arm_group_label>Insulin-Sensitive</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (BMI):  &lt; 25 kg/m2 or &gt; 30 kg/m2;

          -  Insulin sensitivity index (ISI): insulin-sensitive ISI ≥ 7, insulin-resistant ISI ≤
             5.

        Exclusion Criteria:

          -  Medication or supplements known to affect either endothelial function or lipid
             metabolism (i.e. arginine, protein, fish oil)

          -  Acute illness

          -  Uncontrolled metabolic disease, including liver or renal disease

          -  Atrial fibrillation, history of syncope, limiting or unstable angina, congestive
             heart failure, known or suspected right-to-left, bi-directional or transient
             right-to-left cardiac shunts

          -  Cardiac pacemaker or other medical device implanted in the body

          -  Pulmonary hypertension or other unstable cardiopulmonary conditions

          -  ECG documented abnormalities or valvular disease

          -  Low hemoglobin or hematocrit (i.e., lower than accepted laboratory values)

          -  History of hypertension or elevated blood pressure (systolic, &gt;140 mmHg or a
             diastolic, &gt;95 mmHg)

          -  History of hyperlipidemia or plasma triglyceride concentration &gt;200 mg/dl

          -  Diagnosed diabetes, or 2-h plasma glucose &gt;200 mg/dl during an oral glucose tolerance
             test

          -  Current participation in a weight-loss regimen, including extreme dietary practices

          -  Use of anabolic steroids or corticosteroids (within 3 months)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lori Roust, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christos S Katsanos, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Arizona State University/Mayo Clinic Arizona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Early, RN</last_name>
      <phone>480-301-4142</phone>
      <email>early.jennifer@mayo.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 8, 2014</lastchanged_date>
  <firstreceived_date>May 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Lori R. Roust</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Omega-N-Methylarginine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
